Literature DB >> 6383303

Electroretinographic oscillatory potentials predict progression of diabetic retinopathy. Preliminary report.

G H Bresnick, K Korth, A Groo, M Palta.   

Abstract

The oscillatory potential (OP) amplitudes of the electroretinogram (ERG) were determined in a group of 85 diabetic patients entering the Early Treatment Diabetic Retinopathy Study (ETDRS). The rate of progression among nonphotocoagulated eyes to the Diabetic Retinopathy Study high-risk characteristics (DRS-HRC) during a ten- to 40-month follow-up period was determined. Progression occurred in 19 of 85 eyes at risk. Those eyes with abnormal OP amplitudes (less than or equal to 75 microV) at study entry had a tenfold higher rate of progression to DRS-HRC than did eyes with normal amplitudes (greater than 75 microV). Although the level of retinopathic severity at study entry was a significant factor in the rate of subsequent progression, the amplitudes of the OPs remained a significant risk factor even after correcting the initial retinopathic level. The ERG seems to be a useful clinical tool in predicting the rate of progression of diabetic retinopathy. The reduction in OP amplitudes probably is a quantitative measure of the degree of overall inner layer retinal ischemia.

Entities:  

Mesh:

Year:  1984        PMID: 6383303     DOI: 10.1001/archopht.1984.01040031057023

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  65 in total

1.  Distribution of oscillatory components in the central retina.

Authors:  M A Bearse; Y Shimada; E E Sutter
Journal:  Doc Ophthalmol       Date:  2000       Impact factor: 2.379

2.  Measurement of the oscillatory potential of the electroretinogram in the domains of frequency and time.

Authors:  X X Li; N Yuan
Journal:  Doc Ophthalmol       Date:  1990-11       Impact factor: 2.379

3.  The effects of levodopa and haloperidol on flash and pattern ERGs and VEPs in normal humans.

Authors:  P Bartel; M Blom; E Robinson; C van der Meyden; D K Sommers; P Becker
Journal:  Doc Ophthalmol       Date:  1990-11       Impact factor: 2.379

Review 4.  A multifocal electroretinogram model predicting the development of diabetic retinopathy.

Authors:  Marcus A Bearse; Anthony J Adams; Ying Han; Marilyn E Schneck; Jason Ng; Kevin Bronson-Castain; Shirin Barez
Journal:  Prog Retin Eye Res       Date:  2006-09-01       Impact factor: 21.198

5.  Relationships between the electroretinogram a-wave, b-wave and oscillatory potentials and their application to clinical diagnosis.

Authors:  H Asi; I Perlman
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

6.  Changes in multifocal oscillatory potentials after internal limiting membrane removal for macular hole: multifocal OPs after ILM removal.

Authors:  Kazuha Ogata; Shuichi Yamamoto; Yoshinori Mitamura; Takeshi Sugawara; Satoshi Mizunoya
Journal:  Doc Ophthalmol       Date:  2007-02-06       Impact factor: 2.379

7.  Cone Photoreceptor Dysfunction in Early-Stage Diabetic Retinopathy: Association Between the Activation Phase of Cone Phototransduction and the Flicker Electroretinogram.

Authors:  J Jason McAnany; Jason C Park
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-01-02       Impact factor: 4.799

8.  Reduction of Glut1 in the Neural Retina But Not the RPE Alleviates Polyol Accumulation and Normalizes Early Characteristics of Diabetic Retinopathy.

Authors:  Nicholas C Holoman; Jacob J Aiello; Timothy D Trobenter; Matthew J Tarchick; Michael R Kozlowski; Emily R Makowski; Darryl C De Vivo; Charandeep Singh; Jonathan E Sears; Ivy S Samuels
Journal:  J Neurosci       Date:  2021-02-23       Impact factor: 6.167

9.  Presence and further development of retinal dysfunction after 3-year follow up in IDDM patients without angiographically documented vasculopathy.

Authors:  M A Di Leo; S Caputo; B Falsini; V Porciatti; A V Greco; G Ghirlanda
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

10.  Oscillatory potentials of multifocal electroretinogram retinopathy.

Authors:  Hiroyuki Onozu; Shuichi Yamamoto
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.